Patrick Lamy is VP at Akero Therapeutics, Inc. (AKRO). They have made 4 open-market trades across 1 company since 2024, most recently 2025-12-09.
CIK 0001961273
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AKRO | 29,891 | $1.6M |
Shares reported on the most recent Form 4, priced at the 2025-07-03 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AKRO | SELL · 10b5-1 | 2025-07-01 | 2025-07-03 | $52.88 | $106K | +3.4% | -6.2% | -10.2% |
| AKRO | SELL | 2025-06-20 | 2025-06-20 | $54.59 | $48K | -3.3% | -4.2% | -13.9% |
| AKRO | SELL · 10b5-1 | 2025-06-16 | 2025-06-20 | $54.14 | $108K | -3.3% | -4.2% | -13.9% |
| AKRO | SELL | 2025-06-10 | 2025-06-12 | $54.00 | $50K | +5.5% | +1.0% | -17.1% |
| AKRO | SELL · 10b5-1 | 2025-06-02 | 2025-06-04 | $50.32 | $201K | +5.6% | -2.4% | -14.0% |
| AKRO | SELL · 10b5-1 | 2025-05-22 | 2025-05-23 | $50.00 | $200K | +13.6% | +13.7% | +1.7% |
| AKRO | SELL · 10b5-1 | 2025-05-07 | 2025-05-09 | $42.50 | $680K | +20.6% | +36.4% | +25.8% |
| AKRO | SELL · 10b5-1 | 2025-03-03 | 2025-03-05 | $48.09 | $48K | +0.6% | -17.6% | +15.8% |
| AKRO | SELL · 10b5-1 | 2025-01-27 | 2025-01-29 | $57.03 | $285K | -8.2% | -11.9% | -22.8% |
| AKRO | SELL · 10b5-1 | 2024-12-16 | 2024-12-18 | $29.13 | $29K | -2.7% | -12.1% | +52.3% |
| AKRO | SELL | 2024-12-10 | 2024-12-12 | $30.79 | $28K | +0.0% | -20.7% | +60.6% |
| AKRO | SELL | 2024-06-11 | 2024-06-13 | $22.64 | $13K | -5.2% | +13.4% | +5.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.